Biotech
-
Permission granted by Zealand Pharma
Q&A // First 90 DaysLilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
By Amy Baxter • May 21, 2025 -
Stock via Getty Images
The placebo effect: How a new FDA rule could pile more strain onto vaccine developers
The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.
By Alexandra Pecci • May 20, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Philip Pacheco via Getty Images
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.
By Meagan Parrish • May 16, 2025 -
Permission granted by Editas
Q&A // First 90 DaysA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.
By Michael Gibney • May 15, 2025 -
Sedat Suna via Getty Images
Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy
But the therapies will need to prove their worth in the clinic over the next few years.
By Kelly Bilodeau • May 12, 2025 -
Stock via Getty Images
AI is already delivering pharma value — and not just in drug discovery
While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.
By Meagan Parrish • May 12, 2025 -
Jacob Bell/PharmaVoice
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
Stock via Getty Images
Prasad’s FDA appointment pressures cell and gene therapy stocks
A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
By Ben Fidler • May 7, 2025 -
Stock via Getty Images
After an up and down year, pharma’s R&D landscape is shifting again
While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.
By Kelly Bilodeau • May 5, 2025 -
Stock via Getty Images
Is pharma ready to let go of animal testing?
Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.
By Meagan Parrish • May 2, 2025 -
Stock via Getty Images
Q&ACan real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
By Michael Gibney • May 1, 2025 -
Stock via Getty Images
US backlash against mRNA vaccines could hinder scientific progress
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
By Michael Gibney • April 29, 2025 -
Stock via Getty Images
What’s being cut at NIH
A look at the government’s far-reaching rollback in research grants so far.
By Meagan Parrish • April 25, 2025 -
Permission granted by Flagship Pioneering
Flagship’s latest venture reflects more than 25 years of leaping into the unknown
A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.
By Michael Gibney • April 24, 2025 -
Stock via Getty Images
How a scrapped Pfizer drug became a winner for SpringWorks
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
By Alexandra Pecci • April 21, 2025 -
Stock via Getty Images
A big moment is coming for psychedelics
Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.
By Meagan Parrish • April 18, 2025 -
Stock via Getty Images
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub
Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments.
By Alexandra Pecci • April 16, 2025 -
Stock via Getty Images
‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?
The biotech market is taking a beating amid Trump’s turbulent economic policies.
By Amy Baxter • April 15, 2025 -
Kevin Frayer via Getty Images
US risks losing biotech edge to China, report warns
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
By Ned Pagliarulo • April 9, 2025 -
Permission granted by Michelle Werner
ProfileHer son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
By Michael Gibney • April 8, 2025 -
Stock via Getty Images
A birth control pill for men makes moves in the clinic
So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?
By Kelly Bilodeau • April 7, 2025 -
Stock via Getty Images
The year’s biggest biotech haul shows investors are still chasing the AI dream
Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.
By Meagan Parrish • April 4, 2025 -
Kevin Dietsch via Getty Images
OpinionIndustry leaders react to HHS being ‘reduced to a shell’
What healthcare watchdogs have said about the far-reaching job cuts this week.
By Meagan Parrish and Amy Baxter • April 3, 2025 -
Permission granted by Pfizer
ProfileFormer Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
By Michael Gibney • April 1, 2025 -
Stock via Getty Images
With government health info in limbo, drugmakers lose credible sources
The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.
By Alexandra Pecci • April 1, 2025
